Abstract
Objective To investigate the capability of 99Tcm-tricine-EDDA/HYNIC-SFSIIHTPILPL(SP94) as a specific probe for HCC imaging. Methods HYNIC-SP94 peptide was prepared by solid phase synthesis, followed by 99Tcm labeling with tricine-EDDA as the coligand. After determination of radiochemical purity and stability, cell binding study was carried out by incubating Huh-7 cells with 99Tcm-tricine-EDDA/HYNIC-SP94 at different specific activities (2.5, 4.0 and 30.0 GBq/μmol). The biodistribution studies and microSPECT/CT imaging were performed in Huh-7 tumor-bearing mice (study group) and Hela tumor-bearing mice (control group). Statistical analysis was by two-sample t test. Results 99Tcm-tricine-EDDA/HYNIC-SP94 was synthesized with over 95% of labeling yield, which remained stable in saline and FBS up to 12 h. With increasing concentrations of 99Tcm-tricine-EDDA/HYNIC-SP94, Huh-7 cell binding increased but became gradually saturated. In biodistribution studies, (1.02±0.26) %ID/g of tracer was accumulated in Huh-7 tumors at 0.5 h after injection of 99Tcm-tricine-EDDA/HYNIC-SP94, higher than that in the HYNIC-SP94 blocking group ((0.34±0.09) %ID/g; t=3.537, P<0.05). Compared to Hela tumors, Huh-7 tumors were clearly visualized by microSPECT/CT, with which better imaging quality could be achieved with higher specific radioactivity. Conclusion 99Tcm-tricine-EDDA/HYNIC-SP94 could achieve a high labeling efficiency and good in vitro stability as a potential diagnostic tracer specifically targeted for HCC. Key words: Peptides; Isotope labeling; Technetium; Carcinoma, hepatocellular; Tomography, emission-computed, single-photon; Tomography, X-ray computed; Mice, nude
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call